Associate Professor, Internal Medicine, Ohio State University College of Medicine
Hematology
Dr. Robert A. Baiocchi, MD
|
|
Give Review
Robert A. Baiocchi practices Hematology. He graduated from The Ohio State University College of Medicine. He over the years received 17 awards: "Early Career Innovator of the Year Nomination", "CMS Meaningful Use Stage 1 Certification", "Innovation Award-Semi Finalist Inventor of the Year Nomination", "Innovator of the Year Nomination", "Top Eight Faculty Teachers Excellence in Teaching Award", "Top Ten Faculty Teachers Excellence in Teaching Aware", "Distinguished Undergraduate Research Mentor", "Scholar", "Clinical Research Loan and Repayment Award", "Award for Outstanding Research in Internal Medicine", "T32 Research Fellowship", "Medical Student Research Award", "Medical Student Scholar", "Travel Award", "Tuition Scholarship for Graduate Studies", "Sigma XI Scientific Research Honor" and "Mark Diamond Research Foundation Award". Robert Baiocchi is also published. He has 68 publications published. The lastest publication: "Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- The dual epigenetic role of PRMT5 in Acute myeloid leukemia: gene activation and repression via histone arginine methylation.
- Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-Cell transformation.
- The Epstein-Barr virus lytic protein BZLF1 as a candidate target antigen for vaccine development.
- Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma.
- Human Leukocyte Antigen Type and Posttransplant Lymphoproliferative Disorder.
- A phase 1 study of vorinostat maintenance after autologous transplant in high-risk Lymphoma.
- Targeting PI3-kinase (PI3K), AKT and mTOR axis in Lymphoma.
- Driving toward targeted therapy for LCH.
- The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative Disease.
- Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin Lymphoma is associated with prolonged progression-free survival.
- Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.
- Protein Arginine Methyltransferase 5 Inhibition Induces Lymphoma Cell Death Through Reactivation of the Retinoblastoma Tumor Suppressor Pathway and Polycomb Repressor ...
- Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory Non-Hodgkin's Lymphoma.
- Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic Leukemia.
- Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle Cell lymphoma.
- Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol.
- Lymphomatoid Granulomatosis Presenting with Gingival Involvement in an Immune Competent Elderly Male.
- Synthesis, Biological Evaluation, and Radioiodination of Halogenated closo-Carboranylthymidine Analogues (1).
- FTY720 increases CD74 expression and sensitizes mantle Cell lymphoma Cells to milatuzumab-mediated Cell death.
- Versatility of PRMT5-induced methylation in growth control and development.
- Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle Cell lymphoma.
- Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle Cell and follicular lymphoma.
- Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome.
- The search for an optimal DNA, RNA, and protein detection by in Situ hybridization, immunohistochemistry, and solution-based methods.
- The PD-1/PD-L1 axis modulates the natural killer Cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
- FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle Cell lymphoma.
- Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid Leukemia.
- Flavopiridol, fludarabine, and rituximab in mantle Cell lymphoma and indolent B-Cell lymphoproliferative disorders.
- The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-Cell malignancies in vitro and in vivo.
- Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle Cell lymphoma.
- Primary Central nervous system lymphomatoid granulomatosis in a patient receiving azathioprine therapy.
- Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in Acute myeloid leuk...
- EBV-encoded dUTPase induces immune dysregulation: Implications for the pathophysiology of EBV-associated Disease.
- Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell Leukemia.
- IL-15 but not IL-2 rapidly induces lethal xenogeneic Graft-versus-host disease.
- The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene.
- Stress-associated changes in the steady-state expression of latent Epstein-Barr virus: implications for chronic fatigue syndrome and Cancer.
- A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer Cells.
- IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative Disease in hu PBL-SCID mice.
- Selective efficacy of depsipeptide in a xenoGraft model of Epstein-Barr virus-positive lymphoproliferative disorder.
- Combination immunotherapy of B-Cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
- Recent developments in the biology and therapy of T-Cell and natural killer-Cell lymphomas.
- Experimental treatment of Epstein-Barr virus-associated primary Central nervous system lymphoma.
- Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-Cell restoration.
- PRMT5 is upregulated in Malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.).
- Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly.
- Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic Leukemia.
- Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle Cell lymphoma.
- The absence of CD20 messenger RNA in recurrent cutaneous B-Cell lymphoma following rituximab therapy.
- Epstein-Barr virus- and human herpesvirus 8-associated primary cutaneous plasmablastic Lymphoma in the setting of renal transplantation.
- Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10.
- Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer Cells in vitro.
- Phenotypic and functional analysis of Fas (CD95) expression in primary Central nervous system lymphoma of patients with acquired immunodeficiency syndrome.
- Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated Cancer.
- Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.
- Endogenous CD8+ T Cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder.
- Cytokines in the evolution and treatment of AIDS-Lymphoma.
- Cytokine replacement in patients with HIV-1 non-Hodgkin's Lymphoma: the rationale for low-dose interleukin-2 therapy.
- GM-CSF and IL-2 induce specific Cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder.
- The functional characterization of interleukin-10 receptor expression on human natural killer Cells.
- Does previous surgery influence the asymmetric distribution of endometriotic lesions?
- Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin Lymphoma.
- Oral plasmablastic Lymphomas in AIDS patients are associated with human herpesvirus 8.
- Methylation of histone H3 and H4 by PRMT5 regulates ribosomal RNA gene transcription.
- A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.
- Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin Lymphoma: dose-limiting myelosuppres...
- A Novel Histone Deacetylase Inhibitor, AR-42, Reactivates HIV-1 from Chronically and Latently Infected CD4(+) T-Cells.
Schools
Ohio State University College Of Medicine and Public Health
Oh State University Hospital
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Basal Cell Carcinoma
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- Early Career Innovator of the Year Nomination
- CMS Meaningful Use Stage 1 Certification
- Innovation Award-Semi Finalist Inventor of the Year Nomination
- Innovator of the Year Nomination
- Top Eight Faculty Teachers Excellence in Teaching Award
- Top Ten Faculty Teachers Excellence in Teaching Aware
- Distinguished Undergraduate Research Mentor
- Scholar
- Clinical Research Loan and Repayment Award
- Award for Outstanding Research in Internal Medicine
- T32 Research Fellowship
- Medical Student Research Award
- Medical Student Scholar
- Travel Award
- Tuition Scholarship for Graduate Studies
- Sigma XI Scientific Research Honor
- Mark Diamond Research Foundation Award
Education
-
Ohio State University Hospital -
The Ohio State University College of Medicine
Hospital
-
Ohio State University Wexner Medical Center
Drug Facts
| NPI NUMBER | 1770599755 | |
| NPPES Provider LastName | BAIOCCHI | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 432101280 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology | |
| Total Claim Count | 135.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 23.0 | |
| Percent Opioid Claims | 17.04 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1770599755 |
| Last Name Of The Provider | BAIOCCHI |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
Dr. Ahmed M. Ghany, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Peter J. Kourlas, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Alison R. Walker, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark H. Knapp, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erin M. Bertino, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Thomas E. Olencki, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James L. Chen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William L. Marsh Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charalampos A. Spiridonidis, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Robert D. Rupert Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ryan M. Carr, MD |
|
|
Dr. Richard R. Love, MD |
|
|
Dr. Nicole R. Grieselhuber, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tzu-Fei Wang, MD |